Trials / Completed
CompletedNCT00237991
Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population
A Multicentric, Post-Marketing Surveillance to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals Hepatitis A Vaccine Administered in Korean Population.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
GlaxoSmithKline Korea has submitted a registration file for its hepatitis A vaccine. The present study will collect clinical data in the local target population as per the requirement of Korean Food and Drugs administration (FDA).
Detailed description
All subjects will be administered one dose of the hepatitis A vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Hepatitis A |
Timeline
- Start date
- 2005-06-01
- First posted
- 2005-10-13
- Last updated
- 2008-10-16
Source: ClinicalTrials.gov record NCT00237991. Inclusion in this directory is not an endorsement.